

Contact:

Kathryn Morris

KMorrisPR

845-635-9828

**Vitae Pharmaceuticals President John J. Baldwin Inducted into  
American Chemical Society Division of Medicinal Chemistry Hall of Fame**

***Award Recognizes Outstanding Contribution to Medicinal Chemistry***

Fort Washington, PA – August 23, 2007 – Vitae Pharmaceuticals, Inc., an emerging pharmaceutical company dedicated to the discovery and development of innovative drugs, announced today that John J. Baldwin, Ph.D., Vitae's co-founder, President and Chief Scientific Officer, was inducted into the American Chemical Society (ACS) Division of Medicinal Chemistry Hall of Fame at a ceremony held at the ACS annual fall meeting in Boston on August 22, 2007.

The ACS Division of Medicinal Chemistry Hall of Fame was established to recognize overall outstanding contribution to medicinal chemistry through a combination of research, teaching and service. Only three scientists are inducted into the Hall of Fame each calendar year. The Division of Medicinal Chemistry, with the goal of stimulating progress in medicinal chemistry research, is one of the largest divisions of the American Chemical Society. It has more than 10,000 members worldwide dedicated to the discovery and development of new therapeutic agents.

“All of us at Vitae are very proud that Jack's many contributions to drug discovery and development are being recognized by induction into the Hall of Fame,” said Jeffrey Hatfield, CEO of Vitae Pharmaceuticals. “He has been a remarkable and progressive leader in medicinal chemistry throughout his distinguished career. Not only has Jack been a tremendously prolific discoverer of valuable medicines that are used worldwide

to treat a variety of diseases, but he has also been a lifelong pioneer in creating better and faster ways to drive successful drug discovery. In the early 90's, Jack became a leader in the development of large-scale combinatorial chemistry, and he co-founded a company that has since advanced several compounds into clinical development based on his concepts. Then in 2001, Jack developed a passionate interest in creating a breakthrough in drug discovery speed and accuracy through the creation of a revolutionary new structure based drug design system, and Vitae was born from that passion. We are already seeing the fruits of Jack's ideas and are advancing a number of programs toward the clinic in the cardiovascular, CNS, cancer and metabolic fields. I congratulate Jack and thank him for his extraordinary vision.”

Prior to founding Vitae Pharmaceuticals, Dr. Baldwin spent nine years at Pharmacopeia, Inc., where he was a co-founder and served as Chief Scientific and Technology Officer. Prior to Pharmacopeia, Dr. Baldwin was a Distinguished Senior Scientist at Merck & Co., where he spent 33 years in various scientific and management positions. He has authored more than 100 publications; has been a guest-lecturer at over 125 national and international scientific programs; holds over 180 U.S. issued patents; and has been associated with several successful drugs including Pepcid, Trusopt, Cosopt, Crixivan and Agristat.

### **About Vitae Pharmaceuticals**

Vitae Pharmaceuticals is an emerging pharmaceutical company dedicated to the discovery and development of innovative drugs by advancing its pipeline of product candidates. Vitae is uniquely able to discover innovative compounds by accelerating and enhancing the drug discovery skills and experience of its drug hunters with world-class, proprietary drug design technologies developed in collaboration with Intel Corporation. Vitae Pharmaceuticals is financed by leading corporate and venture capital investors and is headquartered in Fort Washington, Pennsylvania. For additional information, please visit the company's website, [www.vitaepharma.com](http://www.vitaepharma.com).